Advertisement

CardioVascular and Interventional Radiology

, Volume 41, Issue 11, pp 1799–1802 | Cite as

Y-90 Radioembolization Combined with a PD-1 Inhibitor for Advanced Hepatocellular Carcinoma

  • Eric Wehrenberg-Klee
  • Lipika Goyal
  • Matthew Dugan
  • Andrew X. Zhu
  • Suvranu Ganguli
Case Report

Abstract

Nivolumab has recently received approval by the Food and Drug Administration for treatment of advanced hepatocellular carcinoma (HCC) in patients previously treated with sorafenib. Nivolumabs’ overall response rate of 20% (El-Khoueiry et al. in Lancet 389:2492–2502, 2017) is a step forward for these patients, but there is significant room for improvement. We describe a case of combining Y-90 radioembolization with nivolumab for treatment of angioinvasive HCC, which successfully bridged patient to partial hepatectomy. Surgical pathology showed negative margins with complete pathological response. With the introduction of immunotherapy for HCC, combining Y-90 radioembolization with immunotherapy may enhance the anti-tumoral immune response of checkpoint inhibitors.

Keywords

Radioembolization Hepatocellular carcinoma Immunotherapy Y-90 Nivolumab Checkpoint inhibitors 

Notes

Compliance with Ethical Standards

Conflict of interest

Suvranu Ganguli is a proctor for SIRTEX medical. The other authors have no conflicts of interest.

Consent for Publication

Consent for publication was obtained for every individual person’s data including the study.

Ethical Approval and Informed Consent

This study has obtained IRB approval from the Massachusetts General Hospital IRB and the need for informed consent was waived.

References

  1. 1.
    El-Khoueiry AB, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet. 2017;389:2492–502.CrossRefGoogle Scholar
  2. 2.
    Twyman-Saint Victor C, et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature. 2015;520:373–7.CrossRefGoogle Scholar
  3. 3.
    Lee Y, et al. Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment. Blood. 2009;114:589–95.CrossRefGoogle Scholar
  4. 4.
    Reits EA, et al. Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. J Exp Med. 2006;203:1259–71.CrossRefGoogle Scholar
  5. 5.
    Gameiro SR, et al. Radiation-induced immunogenic modulation of tumor enhances antigen processing and calreticulin exposure, resulting in enhanced T-cell killing. Oncotarget. 2014;5:403–16.CrossRefGoogle Scholar
  6. 6.
    Filatenkov A, et al. Ablative tumor radiation can change the tumor immune cell microenvironment to induce durable complete remissions. Clin Cancer Res. 2015;21:3727–39.CrossRefGoogle Scholar
  7. 7.
    Park SS, et al. PD-1 restrains radiotherapy-induced abscopal effect. Cancer Immunol Res. 2015;3:610–9.CrossRefGoogle Scholar
  8. 8.
    Dewan MZ, et al. Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody. Clin Cancer Res. 2009;15:5379–88.CrossRefGoogle Scholar
  9. 9.
    Deng L, et al. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J Clin Invest. 2014;124:687–95.CrossRefGoogle Scholar
  10. 10.
    Ayaru L, et al. Unmasking of alpha-fetoprotein-specific CD4(+) T cell responses in hepatocellular carcinoma patients undergoing embolization. J Immunol. 2007;178:1914–22.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature and the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) 2018

Authors and Affiliations

  • Eric Wehrenberg-Klee
    • 1
  • Lipika Goyal
    • 2
  • Matthew Dugan
    • 3
  • Andrew X. Zhu
    • 2
  • Suvranu Ganguli
    • 1
  1. 1.Department of RadiologyMassachusetts General HospitalBostonUSA
  2. 2.Massachusetts General Hospital Cancer CenterBostonUSA
  3. 3.New England Cancer Care SpecialistsScarboroughUSA

Personalised recommendations